Kingfriend

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (referred to as "Kingfriend", stock code: 603707) is located in the Nanjing Jiangbei New Area, with a registered capital of 718.5 million RMB and is a joint-stock company. Established in 2000, the company was formerly known as Nanjing No. 2 Biochemical Pharmaceutical Factory. It was one of the early pharmaceutical enterprises in China to engage in the extraction, purification of heparin, and the development of methods for confirming the structure of heparin-like mucopolysaccharide products. With over 20 years of experience in the production of heparin products, the company is currently the world's largest supplier of heparin active pharmaceutical ingredients (API). Listed on the Shanghai Stock Exchange A-shares on July 19, 2017, the company’s market value exceeds 35 billion RMB. The group has been expanding its strong cooperation with international pharmaceutical giants such as Pfizer, Sanofi, and Novartis while deepening its API business at the Nanjing headquarters. Additionally, it has invested nearly 500 million RMB in building a formulation R&D and production base in Nanjing. In March 2016, the company successfully acquired an exclusive U.S.-based R&D and production facility that had received nearly 500 million RMB in investment in China, forming a beneficial complementary relationship with the group in terms of formulation R&D, registration, and production.